Улипристала ацетат в лечении миомы матки. Как медикаментозное лечение меняет существующие парадигмы?

1. Ahrendt HJ, Tylkoski H, Rabe T et al. Prevalence of uterine myomas in women in Germany: data of an epidemiological study. Arch Gynecol Obstet 2016; 293 (6): 1243–53.
2. Merrill RM. Hysterectomy surveillance in the United States, 1997 through 2005. Med Sci Monit 2008; 14 (1): CR24–31.
3. Whiteman MK, Hillis SD, Jamieson DJ et al. Inpatient hysterectomy surveillance in the United States, 2000–2004. Am J Obstet Gynecol 2008; 198 (1): 34.e1–7.
4. Buie VC, Owings MF, DeFrances CJ, Golosinskly A. National Hospital Discharge Survey: 2006 summary. National Center for Health Statistics. 2010. Available at: www.cdc.gov/nchs/data/series/sr_13/sr13_168.pdf
5. Howard BV, Kuller L, Langer R et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Womens Health Initiative Observational Study. Circulation 2005; 111 (12): 1462–70.
6. Phung TK, Waltoft BL, Laursen TM et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Dis 2010; 30 (1): 43–50.
7. Read MD, Edey KA, Hapeshi J, Foy C. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int 2010; 16 (2): 56–9.
8. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 2011; 32 (6): 745–50.
9. Melton LJ, Achenbach SJ, Gebhart JB et al. Influence of hysterectomy on long-term fracture risk. Fertil Steril 2007; 88 (1): 156–62.
10. Blandon RE, Bharucha AE, Melton LJ et al. Incidence of pelvic floor repair after hysterectomy: a population-based cohort study. Am J Obstet Gynecol 2007; 197 (6): 664, e1–e7.
11. Rocca WA, Bower JH, Maraganore DM et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69 (11): 1074–83.
12. Rocca WA, Grossardt BR, Geda YE et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008; 15 (6): 1050–9.
13. Rocca WA, Bower JH, Maraganore DM et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70 (3): 200–9.
14. Altman D, Yin L, Johansson A et al. After Hysterectomy. Arch Intern Med 2010; 170 (22): 2011–6. DOI: 10.1001/archinternmed.2010.425
15. Chan CC, Ng EH, Ho PC. Ovarian changes after abdominal hysterectomy for benign conditions. J Soc Gynecol Invest 2005; 12 (1): 54–7.
16. Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG 2005; 112 (7): 956–62.
17. Moorman PG, Myers ER, Schildkraut JM et al. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol 2011; 118 (6): 1271–9.
18. Parker WH, Broder MS, Liu Z et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106 (2): 219–26.
19. Rocca WA, Ulrich LG. Oophorectomy for whom and at what age? Primum non nocere. Maturitas 2012; 71 (1): 1–2.
20. Лебедев В.А., Давыдов А.И., Пашков В.М. Спорные и нерешенные вопросы лечения и профилактики миомы матки у больных репродуктивного периода. Трудный пациент. 2013.
[Lebedev V.A., Davydov A.I., Pashkov V.M. Spornye i nereshennye voprosy lecheniia i profilaktiki miomy matki u bol'nykh reproduktivnogo perioda. Trudnyi patsient. 2013 (in Russian).]
21. Ариничева А.B. Влияние эмболизации маточных артерий на функциональное состояние яичников и эндомиометрия у женщин репродуктивного возраста с миомой матки. Дис. …  канд. мед. наук. Барнаул, 2006.
[Arinicheva A.B. The effect of uterine artery embolization on the functional state of the ovaries and endomyometry in women of reproductive age with uterine myoma. Dis. …  kand. med. nauk. Barnaul, 2006 (in Russian).]
22. Van der Kooij SM, Bipat S, Hehenkamp WJ et al. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205 (4): 317.e1–18.
23. Hehenkamp WJ, Volkers NA, Broekmans FJ et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996–2005.
24. Stewart EA, Rabinovici J, Tempany CM et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85 (1): 22–9.
25. Gorny KR, Woodrum DA, Brown DL et al. Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. J Vasc Interv Radiol 2011; 22 (6): 857–64.
26. Bouchard P, Chabbert-Buffet N, Fauser BCJM. Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety. Fertil Steril 2011; 96 (5): 1175–89. DOI: 10.1016/j.fertnstert.2011.08.021
27. Коренная В.В., Подзолкова Н.М. Улипристала ацетат в лечении миомы матки. Гинекология. 2013; 15 (6): 58–61.
[Korennaia V.V., Podzolkova N.M. Ulipristala atsetat v lechenii miomy matki. Gynecology. 2013; 15 (6): 58–61 (in Russian).]
28. Courtoy GE, Henriet P, Marbaix E et al. Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment. J Clin Endocrinol Metab 2018; 103 (4): 1566–73. DOI: 10.1210/jc.2017-02295
29. Courtoy GE, Donnez J, Ambroise J et al. Gene expression changes in uterine myomas in response to ulipristal acetate treatment. Reprod Biomed Online 2018; 37 (2): 224–33. DOI: 10.1016/j.rbmo.2018.04.050
30. Raga F, Pascual C, Boigues D. Cystic degeneration of uterine leiomyoma during ulipristal acetate treatment. Uterus Ovary 2016; 2: e1077.
31. Donnez J, Courtoy GE, Donnez O, Dolmans M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod BioMed Online 2018; 37: 216–23.
32. Donnez J, Arriagada P, Donnez O, Dolmans MM. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr Opin Obstet Gynecol 2015; 27: 422–31.
33. Woodhead N, Pounds R, Irani S, Pradhan P. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. J Obstet Gynaecol 2018; 38 (6): 813–7. DOI: 10.1080/01443615.2017.1405926
34. Simon JA, Catherino W, Blakesley R. Ulipristal acetate treatment of uterine fibroids in black and obese women: VENUS I subgroup analyses [28G]. Obstet Gynecol 2017; 129: 78S–79S.
35. Simon J, Catherino WH, Segars J. First US-based phase 3 study of ulipristal acetate (UPA) for symptomatic uterine fibroids (UF): results of VENUS-I. Fertil Steril 2016; 106 (3): e376.
36. Malone LJ. Myomectomy: recur ence after removal of solitary and multiple myomas. Obstet Gynecol 1969; 34 (2): 200–3.
37. Peddada SD, Laughlin SK, Miner K. Growth of uterine leiomyomata among premenopausal black and white women. Proc Nat Acad Sci U S A 2008.
38. Murji A, Crosier R, Chow T. Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertil Steril 2016; 106 (5): 1165–9.
39. Lee MJ, Yun BS, Seong SJ. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci 2017; 60 (1): 69–73.
40. Mutter GL, Bergeron C, Deligdisch L. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591–8.
41. Laursen JB, Istre O. Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy. J Gynecol Surg 2016; 32 (5): 280–5.
42. Donnez J, Donnez O, Matule D et al. Longterm medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016; 105: 165–73.e4.
43. PRAC recommends new measures to minimize risk of rare but serious liver injury with Esmya for fibroids. Regular liver function testing required during treatment EMA/289137/2018 18 May 2018. http: //www.ema.europa.eu/
44. Donnez J, Vázquez F, Tomaszewski J et al. PEARL III and PEARL III Extension Study Group, 2014. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–73.e1–18.
45. Donnez J, Tomaszewski J, Vázquez F et al. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421–32.
46. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–27.e3.
47. Donnez J, Donnez O, Dolmans MM. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Expert Opin Drug Saf 2016; 15: 1679–86.
48. Luyckx M, Squifflet JL, Jadoul P. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404–9.
49. Hrgovic Z, Habek D, Cerkez Habek J et al. Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma. J Clin Pharm Ther 2018; 43: 121–3.
50. Bizzarri N, Ghirardi V, Remorgida V. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol 2015; 192: 22–6.
51. Ferrero S, Racca A, Tafi E. Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol 2016; 23 (3): 390–5.
52. Ferrero S, Alessandri F, Vellone VG. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 2016; 205: 43–7.
53. Aref-Adib M, Oliver R, Odejinmi F. Esmya and its effects: laparoscopic myomectomy after using ulipristal acetate. Gynecol Surg 2016; 13 (3): 215–80.
54. Wais M, Lee S, Liu G. Surgical experience with ulipristal acetate or gonadotropin releasing hormone agonists for uterine fibroids. J Minim Invasive Gynecol 2016; 23 (7): S1–S252.
55. Fernandez H, Schmidt T, Powell M et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol 2017; 208: 91–6.
56. Murji A, Whitaker L, Chow TL. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017; 4: CD010770.
57. Odejinmi F, Huff KO, Oliver R. Individualisation of intervention for tubal ectopic pregnancy: historical perspectives and the modern evidence based management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 2017; 210: 69–75.
58. Czuczwar P, Wozniak S, Szkodziak P. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study. Ultrasound Obstet Gynecol 2015; 45 (6): 744–50.